The following section of the Fidelis Care authorization grids has been updated effective July 1, 2026.
The following codes have been updated on the Medicaid, CHP, Essential Plan, Ambetter Metal-Level Plans, and Medicare Authorization Grids and require prior authorization:
C9310 leucovorin calcium (avyxa), inj
J1289 narsoplimab-wuug, inj (Yartemlea)
J1577 immune globulin, inj (Qivigy)
J2361 depemokimab-ulaa, inj (Exdensur)
J2789 riboflavin 5'-phosphate, ophthalmic (Epioxahd/Epioxa)
J3386 etuvetidigene autotemcel, inj (Waskyra)
J3405 onasemnogene abeparvovec-brve, inj (Itvisma)
J9053 belantamab mafodotin-blmf, inj (Blenrep)
J9062 amivantamab and hyaluronidase-lpuj, inj (Rybrevant)
J9232 docetaxel (hospira), inj
Q5164 ustekinumab-hmny, inj (Starjemza)
Q5165 denosumab-mobz, inj (Oziltus)
Q5166 denosumab-desu, inj (Osvyrti/Jubereq)
Q5167 denosumab-qbde, inj (Enoby/Xtrenbo)
Q5168 ranibizumab-leyk, inj (Nufymco)
Q5169 pegfilgrastim-unne, inj (Amlupeg)
Q5170 aflibercept-boav, inj (Eydenzelt)
Q5171 denosumab-mobz, inj (Boncresa)
For Medicaid, Essential Plan, Ambetter Metal-Level Plans, and Medicare, the following codes have been added to the list of drugs that require NCH review:
C9310 leucovorin calcium (avyxa), inj
J9053 belantamab mafodotin-blmf, inj (Blenrep)
J9062 amivantamab and hyaluronidase-lpuj, inj (Rybrevant)
J9232 docetaxel (hospira), inj
Q5165 denosumab-mobz, inj (Oziltus)
Q5166 denosumab-desu, inj (Osvyrti/Jubereq)
Q5167 denosumab-qbde, inj (Enoby/Xtrenbo)
Q5169 pegfilgrastim-unne, inj (Amlupeg)
Q5171 denosumab-mobz, inj (Boncresa)
The following codes have been added to the TurningPoint authorization grid and require prior authorization:
93653 Cardiac Ablation
93654 Cardiac Ablation
93656 Cardiac Ablation
93580 Percutaneous Transcatheter Closure
Visit: Authorization Grids